FDA Opens Floor For Debate Of Off-Label Claims, First Amendment Issues
This article was originally published in The Gray Sheet
Executive Summary
FDA's request for comments on First Amendment issues creates a forum for stakeholders to submit comments on FDA's policy regarding off-label claims